If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 14
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refr
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults with rr LBCL
Protocol No
ALLOGENE-ALLO-501A-201
Categories
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-Cell Lymphoma
Split-Dose R-CHOP for Older Adults with DLBCL
Protocol No
WON-SHAH-UW18131-SPLIT-RCHOP
Categories
A Phase Ib, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients with Relapsed/Refractory
A Phase Ib Study Evaluating Glofitamab In Patients With Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma
Protocol No
HOFFMANNLAROCHE-GO43693
Categories
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Loncastuximab Tesirine with Rituximab vs Immunochemotherapy in DLBCL
Protocol No
ADCT-402-311-DLBCL
Categories
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies
A Phase 1 Trial of Tesirine in Patients with B-cell Lymphoid Malignancies
Protocol No
IIT-HAMADANI-ADCT-LONCA
Categories
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Patients with Previously Treated BTK Naïve Mantle Cell Lymphoma
Protocol No
LOXO-BTK-20019
Categories
A Phase 2 Open-Label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)
A Phase 2 Study to Evaluate MK-2140 in Participants With Relapsed or Refractory DLBCL
Protocol No
MERCK-MK2140-004-DLBCL
Categories
A Multicenter, Open-Label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-Cell Malignancies
This project is being done to test the safety of zilovertamab vedotin when given alone or
with nemtabrutinib, and to see how well zilovertamab vedotin works when given alone or with nemtabrutinib to treat B-cell cancers.
with nemtabrutinib, and to see how well zilovertamab vedotin works when given alone or with nemtabrutinib to treat B-cell cancers.
Protocol No
MERCK-MK2140-006-CLL-NHL
Categories